Program
axicabtagene ciloleucel
Also written as “Axicabtagene Ciloleucel”, “Axicabtagene ciloleucel” and “KTE-C19”.
Its studies are mostly in Lymphoma, B-Cell · Lymphoma, Follicular · Lymphoma, Large B-Cell, Diffuse, led by Gilead Sciences.
Furthest: phase 3, since Dec 21, 201710 company-led studies, 3 open or runningNext primary completion: Oct 2030 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciences | 103 open or running | phase 3since Dec 21, 2017 | Oct 5, 2016 | Oct 2030phase 3 · NCT05371093 |
Also a collaborator on its studies: Hoffmann-La Roche and Humanigen.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 5, 2016First study: phase 2 study in Lymphoma, Large B-Cell, DiffuseFirst studyNCT02926833 · 37 enrolled · United States
- Apr 3, 2017Phase 2 study in Lymphoma, FollicularNCT03105336 · 159 enrolled · United States, France
- Dec 21, 2017Phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT03391466 · 359 enrolled · United States, Australia, Austria and more
- Nov 29, 2018Phase 2 study in Lymphoma, B-CellNCT03761056 · 42 enrolled · United States, Australia, France
- Jun 27, 2019Phase 2 study in Refractory Large B-cell LymphomaNCT04002401 · 27 enrolled · United States
- Mar 17, 2020Phase 1 study in RecurrenceNCT04314843 · 6 enrolled · United States
- May 9, 2022Phase 3 study in Lymphoma, FollicularNCT05371093 · 231 enrolled · United States, France, Germany and more
- Jul 13, 2022Phase 2 study in RecurrenceNCT05459571 · 35 enrolled · United States
- Oct 31, 2022Phase 3 study in High-risk Large B-cell Lymphoma (LBCL)NCT05605899 · 300 enrolled · United States, Australia, Austria and more
- Mar 13, 2026Phase 3 study in RecurrenceNCT07479797 · 550 enrolled · United States, Australia, Belgium and more
Ahead
- Oct 2030Primary completion: phase 3 study in Lymphoma, FollicularNCT05371093
- Mar 2031Primary completion: phase 3 study in High-risk Large B-cell Lymphoma (LBCL)NCT05605899
- May 2031Primary completion: phase 3 study in RecurrenceNCT07479797
TargetBeta
CD19 →read by rule
“B-lymphocyte antigen CD19 binding agent”ChEMBL 37, by rule
Other programs on CD19
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| blinatumomabrule | Amgen | phase 4 | 29 |
| inebilizumabrule | Amgen | phase 4 | 19 |
| Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F | AstraZeneca | phase 3 | 12 |
| surovatamig | AstraZeneca | phase 3 | 10 |
| lisocabtagene maraleucelrule | Bristol-Myers Squibb | phase 3 | 10 |
| Anti-CD19/CD3 Bispecific Antibody MK-1045 | Merck | phase 3 | 8 |
| obexelimab | zenas-biopharma-usa-llc | phase 3 | 7 |
| Autologous Anti-CD19 CAR-T Cells CABA-201rule | cabaletta-bio | phase 3 | 6 |
| zolacabtagene autoleucel | Bristol-Myers Squibb | phase 3 | 6 |
| Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753rule | Gilead Sciences | phase 3 | 2 |
| rondecabtagene autoleucelrule | lyell-immunopharma-inc | phase 3 | 2 |
| rapcabtagene autoleucel | Novartis | phase 2 | 8 |
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07479797Recurrence · United States, Australia, Belgium and more | 3 | Active, not recruiting | May 2031 | 550 |
| NCT05605899High-risk Large B-cell Lymphoma (LBCL) · United States, Australia, Austria and more | 3 | Active, not recruiting | Mar 2031 | 300 |
| NCT05459571Recurrence · United States | 2 | Completed | Nov 24, 2025 | 35 |
| NCT05371093Lymphoma, Follicular · United States, France, Germany and more | 3 | Active, not recruiting | Oct 2030 | 231 |
| NCT04314843Recurrence · United States | 1 | Terminated | Mar 16, 2021 | 6 |
| NCT04002401Refractory Large B-cell Lymphoma · United States | 2 | Completed | Jan 30, 2023 | 27 |
| NCT03761056Lymphoma, B-Cell · United States, Australia, France | 2 | Completed | Oct 12, 2023 | 42 |
| NCT03391466Lymphoma, Large B-Cell, Diffuse · United States, Australia, Austria and more | 3 | Completed | Mar 18, 2021 | 359 |
| NCT03105336Lymphoma, Follicular · United States, France | 2 | Completed | Dec 20, 2024 | 159 |
| NCT02926833Lymphoma, Large B-Cell, Diffuse · United States | 2 | Completed | Jan 12, 2023 | 37 |
How it is read
Names in the registry
- “Axicabtagene Ciloleucel”, 8 entries
- “Axicabtagene ciloleucel”, 1 entry
- “KTE-C19”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, B-Cell, 3 studies
- Lymphoma, Follicular, 2 studies
- Lymphoma, Large B-Cell, Diffuse, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.